European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1114-1118 , December 2006

Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction

  • M.J. Forshaw

      Affiliations

    • Department of General Surgery, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • J.A. Gossage

      Affiliations

    • Department of General Surgery, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • K. Chrystal

      Affiliations

    • Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • K. Cheong

      Affiliations

    • Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • S. Atkinson

      Affiliations

    • Department of General Surgery, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • A. Botha

      Affiliations

    • Department of General Surgery, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • P.G. Harper

      Affiliations

    • Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • ,
  • R.C. Mason

      Affiliations

    • Department of General Surgery, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 207 188 2563; fax: +44 207 188 0883.

,Accepted 8 February 2006.

References 

  1. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–385
  2. Lerut T, Coosemans W, De Leyn P, Van Raemdonck D, Deneffe G, Decker G. Treatment of esophageal carcinoma. Chest. 1999;116:463S–465S
  3. O'Sullivan GC, Sheehan D, Clarke A, et al. Micrometastases in esophagogastric cancer: high detection rate in resected rib segments. Gastroenterology. 1999;116:543–548
  4. Kaklamanos IG, Walker GR, Ferry K, Franceschi D, Livingstone AS. Neoadjuvant treatment for respectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis of randomised clinical trials. Ann Surg Oncol. 2003;10:754–761
  5. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540–551
  6. Medical Research Council Oesophageal Cancer Working Party . Surgical resection with or without neoadjuvant chemotherapy in oesophageal cancer: a randomised control trial. Lancet. 2002;359:1727–1733
  7. Highley MS, Parnis FX, Trotter GA, et al. Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma. Br J Surg. 1994;81:1763–1765
  8. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261–267
  9. Andreyev HJN, Norman AR, Cunningham D, et al. Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Eur J Cancer. 1995;31A:2209–2214
  10. Bamias A, Hill ME, Cunningham D, et al. Epirubicin, Cisplatin and protracted venous infusion of 5-Fluorouracil for esophagogastric adenocarcinoma. Cancer. 1996;77:1978–1985
  11. Geh JI, Glynne-Jones R, Kwok QSK, et al. Preoperative ECF chemotherapy in Gastro-oesophageal adenocarcinoma. Clin Oncol. 2000;12:182–187
  12. Melcher AA, Mort D, Maughan TS. Epirubicin, Cisplatin and continuous infusion 5-Fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Cancer. 1996;74:1651–1654
  13. Cunningham D, Allum WH, Stenning SP, Weeden S for the NCRI Upper GI Cancer Clinical Studies Group. Perioperative chemotherapy in operable gastric and lower oesophageal cancer. Final results of a randomised controlled trial (the MAGIC trial ISRCTN 93793971). ASCO abstracts. 2005;4001;(abstract)
  14. In:  Sobin LH,  Wittekind CH editor. TNM classification of malignant tumours. 5th ed.. New York: Wiley-Liss; 1997;
  15. World Health Organisation . WHO handbook for reporting results of cancer treatment (publication no. 48). Geneva: WHO; 1979;
  16. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13–47
  17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  18. Archer VR, Mulholland PJ, Stocken DD, Darnton SJ, Ferry DR. Combined results from three Phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol). 2001;13:164–169
  19. Alderson D. Neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol). 2001;13:153–154
  20. Lerut T, Coosemans W, Decker G, De Leyn P, Nafteux P, Van Raemdonck D. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol. 2001;10:113–122
  21. Forshaw M, Stephens J, Gossage J, et al. Surgical outcomes of oesophagogastrectomy: does neo-adjuvant therapy increase the risk? A retrospective audit. Br J Surg. 2004;91(Suppl. 1):141
  22. McCulloch P, Ward J, Tekkis PP ASCOT group of surgeons, British Oesophago-Gastric Cancer Group. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327:1192–1197
  23. Allum WH, Griffin SM, Watson A, Colin-Jones D Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, British Society of Gastroenterology, British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut. 2002;50(Suppl. 5):v1–v23
  24. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with respectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165–2174
  25. Brucher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30:963–971
  26. Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neoadjuvant therapy in upper gastro-intestinal cancer. J Gastroenterol Hepatol. 2002;17:S172–S175
  27. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058–3065
  28. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45:56–68

☆ Conflicts of interest: None declared.

PII: S0748-7983(06)00111-9

doi: 10.1016/j.ejso.2006.02.025

European Journal of Surgical Oncology
Volume 32, Issue 10 , Pages 1114-1118 , December 2006

Article Tools